English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

A globally suppressed T cell function has been described for cancer patients including patients with chronic lymphatic leukemia (CLL) or multiple myeloma (MM). This has been mainly associated with inhibitory factors released by the tumor cells, while the role of recently characterized regulatory immune cells is not understood. Several different regulatory T cells such as CD4+ CD25+ T cells (Treg), TGFβ producing TH3 or IL-10 producing TR1 cells have been described in murine models, and Treg cells have also been implicated in the control of graft versus host disease after allogeneic transplantation in humans. In contrast, little is known about frequencies and function of regulatory cells in leukemias and lymphomas. To address this issue we have analyzed 82 peripheral blood samples from 24 CLL patients, 18 MM patients and 26 healthy individuals. By assessing CD4+ CD25+ T cells we established a strongly significant increase of this subpopulation in both CLL (13 ± 7% mean ± SD, p < 0.01) and MM (13 ± 9%, p < 0.01) when compared to healthy individuals (3.5 ± 1.5%). While CDC4+ CD25+ T cells could also comprise previously activated T cells, the expression of CTLA4 has been associated with Treg cells. In fact, 80± 14% respectively 67± 26% of CD4+ CD25+ T cells in CLL resp. MM were also CTLA4+, while only 30 ± 22% were found to be positive in healthy individuals strongly suggesting that these cells are mainly Treg cells. In contrast, using the BDCA-4 specific antibody for Neuropilin-1, we were unable to detect this molecule recently described on murine Treg cells on any of our samples. Interestingly, a significant proportion of CD4+ CD25+ T cells in CLL 28 ± 13% and MM 22 ± 12% also expressed intracellular TGFβ, which was only found in 6 ± 4% of these T cells in healthy individuals. Whether TGFβ production reflects a particular activation status of Treg cells or whether these cells are a defined subpopulation requires further investigation. By analyzing co-expression of CCR7 and CD45RA we established that the fraction of CD4+ CD25+ T cells was particularly increased in the naive and the central memory pool in peripheral blood of CLL and MM patients. Next we assessed T cell activation as a function of Treg cells. As expected, there was already a significantly decreased proliferative response of CD4+ T cells in many CLL patients even when CD25+ cells were depleted. These findings are most likely explained by chronic exposure to inhibitory cytokines as well as Treg cells. However, even under these conditions, coculture experiments of CD4+ CD25and CD4+ CD25+ Treg cells supported the inhibitory role of Treg cells in CLL. We therefore propose that immunotherapy in any malignancy including CLL and MM characterized by an increase of regulatory factors and cells will significantly benefit from strategies inhibiting immune repression. from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting Mainz, Germany, 6–7 May 2004

cancer cell international

Increased frequency of CTLA4+ TGFβ+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma